CD4+ T cell immunity against cutaneous melanoma encompasses multifaceted MHC II-dependent responses.
Saved in:
| Title: | CD4+ T cell immunity against cutaneous melanoma encompasses multifaceted MHC II-dependent responses. |
|---|---|
| Authors: | Bawden EG; Department of Microbiology and Immunology, University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia.; Institute of Experimental Oncology (IEO), Medical Faculty, University Hospital Bonn, University of Bonn, Bonn 53105, Germany., Wagner T; Department of Microbiology and Immunology, University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia., Schröder J; Computational Sciences Initiative, Department of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, VIC, Australia., Effern M; Department of Microbiology and Immunology, University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia.; Institute of Experimental Oncology (IEO), Medical Faculty, University Hospital Bonn, University of Bonn, Bonn 53105, Germany., Hinze D; Institute of Experimental Oncology (IEO), Medical Faculty, University Hospital Bonn, University of Bonn, Bonn 53105, Germany., Newland L; Department of Microbiology and Immunology, University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia.; Institute of Experimental Oncology (IEO), Medical Faculty, University Hospital Bonn, University of Bonn, Bonn 53105, Germany., Attrill GH; Melanoma Institute Australia, University of Sydney, Sydney, NSW, Australia.; Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia.; Charles Perkins Centre, University of Sydney, Sydney, NSW, Australia., Lee AR; Department of Microbiology and Immunology, University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia., Engel S; Department of Microbiology and Immunology, University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia., Freestone D; Department of Microbiology and Immunology, University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia., de Lima Moreira M; Department of Microbiology and Immunology, University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia., Gressier E; Department of Microbiology and Immunology, University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia., McBain N; Department of Microbiology and Immunology, University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia., Bachem A; Department of Microbiology and Immunology, University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia., Haque A; Department of Microbiology and Immunology, University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia., Dong R; Computational Sciences Initiative, Department of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, VIC, Australia.; Department of Clinical Pathology and Centre for Cancer Research, University of Melbourne, Melbourne, VIC, Australia., Ferguson AL; Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia.; Charles Perkins Centre, University of Sydney, Sydney, NSW, Australia.; Centenary Institute, University of Sydney, Sydney, NSW, Australia.; Infection, Immunity and Inflammation theme, School of Medical Sciences, Charles Perkins Centre, University of Sydney, Sydney, NSW, Australia., Edwards JJ; Melanoma Institute Australia, University of Sydney, Sydney, NSW, Australia.; Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia.; Charles Perkins Centre, University of Sydney, Sydney, NSW, Australia., Ferguson PM; Melanoma Institute Australia, University of Sydney, Sydney, NSW, Australia.; Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia.; Department of Tissue Oncology and Diagnostic Pathology, Royal Prince Alfred Hospital, Sydney, NSW, Australia.; NSW Health Pathology, Sydney, NSW, Australia., Scolyer RA; Melanoma Institute Australia, University of Sydney, Sydney, NSW, Australia.; Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia.; Charles Perkins Centre, University of Sydney, Sydney, NSW, Australia.; Department of Tissue Oncology and Diagnostic Pathology, Royal Prince Alfred Hospital, Sydney, NSW, Australia.; NSW Health Pathology, Sydney, NSW, Australia., Wilmott JS; Melanoma Institute Australia, University of Sydney, Sydney, NSW, Australia.; Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia.; Charles Perkins Centre, University of Sydney, Sydney, NSW, Australia., Jewell CM; Fischell Department of Bioengineering, University of Maryland, College Park, MD, USA.; United States Department of Veterans Affairs, VA Maryland Health Care System, Baltimore, MD, USA.; Robert E. Fischell Institute for Biomedical Devices, College Park, MD, USA.; Marlene and Stewart Greenebaum Cancer Center, Baltimore, MD, USA., Brooks AG; Department of Microbiology and Immunology, University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia., Gyorki DE; Division of Cancer Surgery, Peter MacCallum Cancer Centre and Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia.; Peter MacCallum Cancer Centre Melbourne, Melbourne, VIC, Australia., Palendira U; Melanoma Institute Australia, University of Sydney, Sydney, NSW, Australia.; Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia.; Charles Perkins Centre, University of Sydney, Sydney, NSW, Australia., Bedoui S; Department of Microbiology and Immunology, University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia., Waithman J; Telethon Kids Institute, University of Western Australia, Perth, WA, Australia.; School of Biomedical Sciences, University of Western Australia, Perth, WA, Australia., Hochheiser K; Department of Microbiology and Immunology, University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia.; Peter MacCallum Cancer Centre Melbourne, Melbourne, VIC, Australia., Hölzel M; Institute of Experimental Oncology (IEO), Medical Faculty, University Hospital Bonn, University of Bonn, Bonn 53105, Germany., Gebhardt T; Department of Microbiology and Immunology, University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia. |
| Source: | Science immunology [Sci Immunol] 2024 Jan 19; Vol. 9 (91), pp. eadi9517. Date of Electronic Publication: 2024 Jan 19. |
| Publication Type: | Journal Article; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: American Association for the Advancement of Science Country of Publication: United States NLM ID: 101688624 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2470-9468 (Electronic) Linking ISSN: 24709468 NLM ISO Abbreviation: Sci Immunol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 2470-9468 |
|---|---|
| DOI: | 10.1126/sciimmunol.adi9517 |
